FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224221846> ?p ?o ?g. }

• W4224221846 endingPage "2050" @default.
• W4224221846 startingPage "2050" @default.
• W4224221846 abstract "Hyperthermia (HT) is an accepted treatment for recurrent breast cancer which locally heats the tumor to 39–44 °C, and it is a very potent sensitizer for radiotherapy (RT) and chemotherapy. However, currently little is known about how HT with a distinct temperature, and particularly, how the sequence of HT and RT changes the immune phenotype of breast cancer cells. Therefore, human MDA-MB-231 and MCF-7 breast cancer cells were treated with HT of different temperatures (39, 41 and 44 °C), alone and in combination with RT (2 × 5 Gy) in different sequences, with either RT or HT first, followed by the other. Tumor cell death forms and the expression of immune checkpoint molecules (ICMs) were analyzed by multicolor flow cytometry. Human monocyte-derived dendritic cells (moDCs) were differentiated and co-cultured with the treated cancer cells. In both cell lines, RT was the main stressor for cell death induction, with apoptosis being the prominent cell death form in MCF-7 cells and both apoptosis and necrosis in MDA-MB-231 cells. Here, the sequence of the combined treatments, either RT or HT, did not have a significant impact on the final outcome. The expression of all of the three examined immune suppressive ICMs, namely PD-L1, PD-L2 and HVEM, was significantly increased on MCF-7 cells 120 h after the treatment of RT with HT of any temperature. Of special interest for MDA-MB-231 cells is that only combinations of RT with HT of both 41 and 44 °C induced a significantly increased expression of PD-L2 at all examined time points (24, 48, 72, and 120 h). Generally, high dynamics of ICM expression can be observed after combined RT and HT treatments. There was no significant difference between the different sequences of treatments (either HT + RT or RT + HT) in case of the upregulation of ICMs. Furthermore, the co-culture of moDCs with tumor cells of any treatment had no impact on the expression of activation markers. We conclude that the sequence of HT and RT does not strongly affect the immune phenotype of breast cancer cells. However, when HT is combined with RT, it results in an increased expression of distinct immune suppressive ICMs that should be considered by including immune checkpoint inhibitors in multimodal tumor treatments with RT and HT. Further, combined RT and HT affects the immune system in the effector phase rather than in the priming phase." @default.
• W4224221846 created "2022-04-26" @default.
• W4224221846 creator A5005230207 @default.
• W4224221846 creator A5013452412 @default.
• W4224221846 creator A5019258439 @default.
• W4224221846 creator A5027231637 @default.
• W4224221846 creator A5030709807 @default.
• W4224221846 creator A5034065380 @default.
• W4224221846 creator A5040406023 @default.
• W4224221846 creator A5062175150 @default.
• W4224221846 creator A5073856969 @default.
• W4224221846 creator A5083060917 @default.
• W4224221846 creator A5083210502 @default.
• W4224221846 date "2022-04-19" @default.
• W4224221846 modified "2023-10-15" @default.
• W4224221846 title "The Effect of Hyperthermia and Radiotherapy Sequence on Cancer Cell Death and the Immune Phenotype of Breast Cancer Cells" @default.
• W4224221846 cites W1513881469 @default.
• W4224221846 cites W1911698430 @default.
• W4224221846 cites W1917033053 @default.
• W4224221846 cites W1928360961 @default.
• W4224221846 cites W1955548161 @default.
• W4224221846 cites W1964692808 @default.
• W4224221846 cites W1971479823 @default.
• W4224221846 cites W1977020389 @default.
• W4224221846 cites W1982862191 @default.
• W4224221846 cites W1994162549 @default.
• W4224221846 cites W2003084559 @default.
• W4224221846 cites W2020096522 @default.
• W4224221846 cites W2026765929 @default.
• W4224221846 cites W2029472440 @default.
• W4224221846 cites W2037653557 @default.
• W4224221846 cites W2037993998 @default.
• W4224221846 cites W2045732739 @default.
• W4224221846 cites W2061025043 @default.
• W4224221846 cites W2090360865 @default.
• W4224221846 cites W2092432271 @default.
• W4224221846 cites W2095493818 @default.
• W4224221846 cites W2097113830 @default.
• W4224221846 cites W2102118972 @default.
• W4224221846 cites W2105252803 @default.
• W4224221846 cites W2106787323 @default.
• W4224221846 cites W2124733312 @default.
• W4224221846 cites W2125941146 @default.
• W4224221846 cites W2138534590 @default.
• W4224221846 cites W2154935750 @default.
• W4224221846 cites W2189381691 @default.
• W4224221846 cites W2262412618 @default.
• W4224221846 cites W2288654589 @default.
• W4224221846 cites W2565997905 @default.
• W4224221846 cites W2566833162 @default.
• W4224221846 cites W2625821474 @default.
• W4224221846 cites W2626453090 @default.
• W4224221846 cites W2763833914 @default.
• W4224221846 cites W2769855452 @default.
• W4224221846 cites W2776144880 @default.
• W4224221846 cites W2779921203 @default.
• W4224221846 cites W2791697339 @default.
• W4224221846 cites W2793704699 @default.
• W4224221846 cites W2899514183 @default.
• W4224221846 cites W2907867527 @default.
• W4224221846 cites W2909350868 @default.
• W4224221846 cites W2911888426 @default.
• W4224221846 cites W2945615688 @default.
• W4224221846 cites W2981106427 @default.
• W4224221846 cites W2990502619 @default.
• W4224221846 cites W2999795356 @default.
• W4224221846 cites W3001906488 @default.
• W4224221846 cites W3008362893 @default.
• W4224221846 cites W3009231574 @default.
• W4224221846 cites W3011642937 @default.
• W4224221846 cites W3016223546 @default.
• W4224221846 cites W3019571657 @default.
• W4224221846 cites W3022548009 @default.
• W4224221846 cites W3033772398 @default.
• W4224221846 cites W3034184823 @default.
• W4224221846 cites W3092468333 @default.
• W4224221846 cites W3098690773 @default.
• W4224221846 cites W3106890323 @default.
• W4224221846 cites W3133206057 @default.
• W4224221846 cites W3134001380 @default.
• W4224221846 cites W3148592396 @default.
• W4224221846 cites W3158713318 @default.
• W4224221846 cites W3189159315 @default.
• W4224221846 cites W3193304256 @default.
• W4224221846 cites W3195175135 @default.
• W4224221846 cites W3207348852 @default.
• W4224221846 cites W3214393981 @default.
• W4224221846 cites W4205492943 @default.
• W4224221846 cites W4206284710 @default.
• W4224221846 cites W4207031694 @default.
• W4224221846 cites W4210473220 @default.
• W4224221846 cites W4210476038 @default.
• W4224221846 cites W4211133027 @default.
• W4224221846 cites W4225265613 @default.
• W4224221846 cites W4246086318 @default.
• W4224221846 doi "https://doi.org/10.3390/cancers14092050" @default.
• W4224221846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35565180" @default.
• W4224221846 hasPublicationYear "2022" @default.

• next